Want to see SLXN full AI Analyst Report?
SLXN Stock Chart & Stats
$2.27
-$0.11(-4.62%)
At close: 4:00 PM EDT
$2.27
-$0.11(-4.62%)
Day’s Range― - ―
52-Week Range$1.50 - $94.60
Previous CloseN/A
Volume10.76K
Average Volume (3M)50.14K
Market Cap
$2.00M
Enterprise Value$3.68
Total Cash (Recent Filing)$2.41M
Total Debt (Recent Filing)$436.00K
Price to Earnings (P/E)<0.1
Beta0.31
Next Earnings
Aug 18, 2026EPS Estimate
-21.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)49.40
Shares Outstanding1,063,117
10 Day Avg. Volume60,134
30 Day Avg. Volume50,136
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.98
Price to Sales (P/S)0.00
P/FCF Ratio-0.24
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-49.3
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical AdvancementMoving SIL204 into an active Phase 2/3 trial is a durable operational de‑risking milestone: it shifts the company from regulatory preparation to data generation, increases potential for partnering or milestone revenue, and materially raises the program's near‑term clinical readout probability.
Manufacturing & Regulatory ReadinessGMP production with a reputable CDMO and ethics/MOH approvals materially reduce operational execution risk. Having clinical batches and regulatory clearances in place supports timely dosing, improves trial credibility with partners, and underpins reliable delivery of clinical endpoints.
Supportive Preclinical BiologyPreclinical data showing increased tumor MHC‑I expression indicates a mechanism to counter immune evasion. This durable biological rationale supports combination strategies with checkpoint inhibitors and expands the potential clinical positioning across KRAS‑driven tumors, strengthening long‑term program value.
Bears Say
No Revenue / Persistent LossesThe company remains pre‑revenue with multi‑period operating losses, meaning it cannot self‑fund development from product cashflows. Structural dependence on clinical success for any revenue elevates commercial risk and forces ongoing reliance on external capital to sustain operations and advance programs.
High Cash BurnSustained negative operating and free cash flow at material levels constrains runway absent financing. Persistent cash burn increases the frequency and size of future capital raises, raising dilution risk and limiting the firm's ability to scale programs or invest in parallel assets without external funding.
Capital Structure / Dilution OverhangMultiple capital actions—warrant inducement, large authorized share increases and confirmed warrant exercisability—create a lasting dilution overhang. While they enhance financing flexibility, they also raise structural shareholder dilution risk and can complicate future financing dynamics and investor returns.
Silexion Therapeutics News
SLXN FAQ
What was Silexion Therapeutics’s price range in the past 12 months?
Silexion Therapeutics lowest stock price was $1.50 and its highest was $94.60 in the past 12 months.
What is Silexion Therapeutics’s market cap?
Silexion Therapeutics’s market cap is $2.00M.
When is Silexion Therapeutics’s upcoming earnings report date?
Silexion Therapeutics’s upcoming earnings report date is Aug 18, 2026 which is in 14 days.
How were Silexion Therapeutics’s earnings last quarter?
Silexion Therapeutics released its earnings results on May 18, 2026. The company reported -$8.5 earnings per share for the quarter, beating the consensus estimate of -$12.9 by $4.4.
Is Silexion Therapeutics overvalued?
According to Wall Street analysts Silexion Therapeutics’s price is currently Overvalued.
Does Silexion Therapeutics pay dividends?
Silexion Therapeutics does not currently pay dividends.
What is Silexion Therapeutics’s EPS estimate?
Silexion Therapeutics’s EPS estimate is -21.2.
How many shares outstanding does Silexion Therapeutics have?
Silexion Therapeutics has 1,063,117 shares outstanding.
What happened to Silexion Therapeutics’s price movement after its last earnings report?
Silexion Therapeutics reported an EPS of -$8.5 in its last earnings report, beating expectations of -$12.9. Following the earnings report the stock price went down -5.363%.
Which hedge fund is a major shareholder of Silexion Therapeutics?
Currently, no hedge funds are holding shares in SLXN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Silexion Therapeutics
Silexion Therapeutics LTD is a biopharmaceutical company specializing in the discovery and advancement of RNA interference (RNAi)-based cancer therapies and their associated delivery systems, with a focus on treating aggressive solid tumors. The company's strategy for addressing these tumors relies on its proprietary LODER delivery platform. Its product pipeline features several key candidates: SiG12D-LODER, which has progressed through both preclinical studies and an open-label Phase I clinical trial for pancreatic cancer; Prostate-LODER, currently undergoing preclinical evaluation for prostate cancer; and GBM-LODER, also in preclinical development, targeting Glioblastoma Multiforme, a highly malignant primary brain tumor. Founded in 2008, Silexion Therapeutics is headquartered in Jerusalem, Israel.
SLXN Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Ownership Overview
54.16% Insiders
<0.01% Other Institutional Investors
45.84% Public Companies and
Individual Investors